NIAMS Building Interdisciplinary Research Team (BIRT) Revision Awards (R01)

The summary for the NIAMS Building Interdisciplinary Research Team (BIRT) Revision Awards (R01) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

NIAMS Building Interdisciplinary Research Team (BIRT) Revision Awards (R01): The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) solicits applications that promote building new interdisciplinary teams among independent investigators for basic or translational research. These teams should pursue a clear and significant scientific opportunity in an area of shared interest of relevance to NIAMS. Interdisciplinary teams can undertake conceptually and technically novel approaches that would be less likely to succeed if undertaken by a more narrowly focused group of investigators. The NIAMS plans to provide up to one year of Revision support to currently active NIAMS R01s (parent grant) to establish such collaborations for high innovation and potentially high impact research. It is understood that such an application may entail high risk. Teams developed under this award are expected to make significant advances beyond the progress anticipated from the individual researchers alone.

Federal Grant Title:	NIAMS Building Interdisciplinary Research Team (BIRT) Revision Awards (R01)
Federal Agency Name:	National Institutes of Health
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-AR-13-003
Type of Funding:	Grant
CFDA Numbers:	93.846
CFDA Descriptions:	Arthritis, Musculoskeletal and Skin Diseases Research
Current Application Deadline:	Jul 15, 2014
Original Application Deadline:	Jul 15, 2014
Posted Date:	Jun 22, 2012
Creation Date:	Jun 22, 2012
Archive Date:	Aug 15, 2014
Total Program Funding:	$1,500,000
Maximum Federal Grant Award:	$100,000
Minimum Federal Grant Award:
Expected Number of Awards:	10
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility: Other Eligible Applicants include the following: Domestic institutions with active NIAMS R01 grants.
Grant Announcement Contact: NIH OER [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [[email protected]]
Similar Government Grants: • Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases (R01 ...; • Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases (R61 ...; • Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Centers (MDSRC) (P50 Cli...; • Core Centers for Clinical Research (CCCR) (P30 Clinical Trial Not Allowed); • NIAMS Skin Biology and Diseases Resource-based Centers (P30 - Clinical Trial Not Allowed); • Collaborative Arthritis and Musculoskeletal and Skin Diseases Science Award (Camssa); • Niams Small Grant Program for New Investigators; • Skin Diseases Research Core Centers
More Grants from the National Institutes of Health: • The NCI Worta McCaskill-Stevens Career Development Award for Community Oncology and Preven...; • Interventions to Reduce Sleep Health Disparities (R01 - Clinical Trials Optional); • Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Tri...; • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...; • HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggabl...